Mon, Dec 29, 2014, 12:43 AM EST - U.S. Markets open in 8 hrs 47 mins

Recent

% | $
Quotes you view appear here for quick access.

MABVAX THERAPEUTICS Message Board

  • skyhigh_x skyhigh_x Jan 25, 2013 3:00 PM Flag

    TELK info:

    Telintra is among the first therapeutic products in a novel class of small-molecule drug candidates which inhibit the enzyme glutathione S-transferase P1-1 for the treatment of malignancies, including myelodysplastic syndrome (MDS) and hematologic diseases characterized by cytopenias. Telintra may induce apoptosis, or cellular death, in leukemia cells and cause differentiation and proliferation of normal bone marrow blood cell precursors, leading to an increase in platelets, red cells, and white cells.

    Telik is seeking strategic partnerships.

    At this price and with its TRAP platform now proven... TELK should finally start moving up to the $6-$8 area like its peers
    .

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Telik's product candidates were discovered using its proprietary drug discovery technology, TRAP®, which enables the rapid and efficient discovery of small molecule drug candidates.

      TELK is for real with studies in the Journal of Hematology & Oncology.

      Telcyta® / canfosfamide HCl / TLK286 glutathione S-transferase P1-1 (GST P1-1) agonist Non Small Cell Lung Cancer (NSCLC) (platinum resistant) III
      Telcyta® / canfosfamide HCl / TLK286 glutathione S-transferase P1-1 (GST P1-1) agonist 3rd line platinum-resistant Ovarian cancer II
      Telintra® / ezatiostat / TLK199 blood cell production stimulator Chemotherapy-induced cytopenia II
      Telintra® / ezatiostat / TLK199 blood cell production stimulator Myelodysplastic Syndrome (MDS) II
      DNA-MT DNA methyltransferase inhibitor Various cancer types Preclinical
      PI3K PI3K inhibitor Various cancer types Preclinical
      PLK-1 polo-like kinase 1 (PLK1) inhibitor Various cancer types Preclinical
      TLK58747 small molecule chemotherapeutic agent Various cancer types Preclinical
      Unnamed aurora kinase/VEGFR2 inhibitor Various cancer types Preclinical
      Unnamed tropomyocin receptor kinase A (TrkA) inhibitor Various cancer types Preclinical
      Unnamed proteasome inhibitor Various cancer types Preclinical
      VEGFR2 VEGFR inhibitor Various cancer types Preclinical

      TELK get in before the next PR

      • 2 Replies to skyhigh_x
      • Very good. Dazzle them with scientific names. I have a question for you.

        Telik has had TRAP for decades and they have always desired to make money by testing other companies drug candidates with their TRAP molecular recognition library evaluation. Years ago, they had a couple of companies actually have Telik evaluate their drug candidates (for a fee, naturally). Can you name any companies that have had success with TRAP screenings so that they have come back with other candidates? Can you name any companies that pay Telik to screen at all, repeat business or not? You will see by their earnings that TRAP is hardly sought after, nor has it been a money maker. The inventor of trap, Dr. Larry Kauvar, left Terrapin/Telik perhaps fourteen plus years ago. Again, Orphan status has been applied for but not yet approved. Go to the FDA site.

      • EDGX and NSDQ grabbing shares... accumulation big time today

 
TELK
5.500.00(0.00%)Oct 9 11:33 AMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.